Internal Reference Number: FOI_7920
Date Request Received: 03/05/2024 00:00:00
Date Request Replied To: 19/06/2024 00:00:00
This response was sent via: By Email
Request Summary: Use of biologic and biosimilar products
Request Category: Companies
| Question Number 1: Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Baricitinib [Olumiant] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Filgotinib [Jyseleca] • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Rituximab [MabThera] • Rituximab Biosimilars • Sarilumab [Kevzara] • Secukinumab [Cosentyx] • Tocilizumab [Ro Actemra] • Tocilizumab Biosimilars • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] | |
| Answer To Question 1: • Abatacept [Orencia] 59 • Adalimumab [Humira] 23 • Adalimumab Biosimilars 218 • Apremilast [Otezla] 7 • Baricitinib [Olumiant] 64 • Bimekizumab [Bimzelx] <5 • Certolizumab [Cimzia] 40 • Etanercept [Enbrel] 14 • Etanercept Biosimilars 161 • Filgotinib [Jyseleca] 26 • Golimumab [Simponi] 26 • Guselkumab [Tremfya] 16 • Infliximab [Remicade] 9 • Infliximab Biosimilars 30 • Ixekizumab [Taltz] 46 • Risankizumab [Skyrizi] 0 • Rituximab [MabThera] 8 • Rituximab Biosimilars 103 • Sarilumab [Kevzara] <5 • Secukinumab [Cosentyx] 18 • Tocilizumab [Ro Actemra] 54 • Tocilizumab Biosimilars 0 • Tofacitinib [Xeljanz] 22 • Upadacitinib [Rinvoq] 67 • Ustekinumab [Stelara] 14 | |
| Question Number 2: Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs: • Abatacept [Orencia] • Adalimumab [Humira] • Adalimumab Biosimilars • Apremilast [Otezla] • Bimekizumab [Bimzelx] • Certolizumab [Cimzia] • Etanercept [Enbrel] • Etanercept Biosimilars • Golimumab [Simponi] • Guselkumab [Tremfya] • Infliximab [Remicade] • Infliximab Biosimilars • Ixekizumab [Taltz] • Risankizumab [Skyrizi] • Secukinumab [Cosentyx] • Tofacitinib [Xeljanz] • Upadacitinib [Rinvoq] • Ustekinumab [Stelara] | |
| Answer To Question 2: • Abatacept [Orencia] 0 • Adalimumab [Humira] <5 • Adalimumab Biosimilars 79 • Apremilast [Otezla] 6 • Bimekizumab [Bimzelx] <5 • Certolizumab [Cimzia] 12 • Etanercept [Enbrel] <5 • Etanercept Biosimilars 29 • Golimumab [Simponi] 9 • Guselkumab [Tremfya] 15 • Infliximab [Remicade] <5 • Infliximab Biosimilars <5 • Ixekizumab [Taltz] 41 • Risankizumab [Skyrizi] 0 • Secukinumab [Cosentyx] 7 • Tofacitinib [Xeljanz] 16 • Upadacitinib [Rinvoq] 9 • Ustekinumab [Stelara] 7 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
